

APOLLO HOSPITALS ENTERPRISE LIMITED

Earnings Update Q2 FY24



Operational & Financial Snapshot



Consolidated Financials

03
Healthcare Services



Diagnostics & Retail Health (AHLL) **U5** Digital Health & Pharmacy Distribution (Apollo HealthCo)



2






Operational & Financial Snapshot

Q2FY24 Operational Snapshot








- Apollomedics Super Specialty Hospital, Lucknow achieved a milestone landmark by performing 100 Successful Solid Organ Transplants. This is the only private hospital in the region to perform Cadaveric Liver & Kidney Transplants
- Apollo Hospitals introduced India's first Comprehensive Connected Care Services nationally. Through this, Apollo will offer clinical teams and nursing staff a holistic real-time view of the patient, across several care touchpoints along the patient journey
- Apollo Hospitals, Jubilee Hills, Hyderabad successfully performed a complex and novel non-surgical mitral valve procedure on a patient with recurrent heart failure.
- Apollo Hospitals expanded its presence in Kolkata with an acquisition of a partially built hospital. This will be Apollo's second hospital in Kolkata and fifth in the eastern region, and Apollo further strengthens its position as the largest healthcare provider in the region with over 1800 beds across Kolkata, Bhubaneshwar and Guwahati.

Q2FY24 Financial Snapshot






1 EBITDA Post INDAS 116 | * Includes 24|7 Operating cost

H1FY24 Financial Snapshot





1 EBITDA Post INDAS 116 | 2 Growth excludes one-off DT reversal of Rs.1466 mio in Q1FY23 * Includes 24 7 Operating cost





Consolidated Financials

Consolidated Financials Q2 FY24



₹ Mio		Healthcare Services	Diagnostics & Retail Health (AHLL)	Digital Health & Pharmacy Distribution (AHE)	Consol
	Total Revenues	25,472	3,542	19,454	48,469
	EBITDA (Pre 24 7 Cost)	6,344	318	1,586	8,248
	margin (%)	24.9%	9.0%	8.2%	17.0%
	24/7 Operating Cost			-1,622	-1,622
	ESOP(Non Cash expense)			-351	-351
Q2 FY 24	EBITDA	6,344	318	-387	6,275
Q2 F1 24	margin (%)	24.9%	9 .0 %	-	12.9%
	EBIT	5,123	30	-512	4,641
	margin (%)	20.1%	0.9%	-	9.6%
	PBT	4,625	-158	-677	3,790
	margin (%)	18.2%	-	-	7.8%
	PAT (Reported)	3,136	-130	-678	2,329
	Total Revenues	22,645	3,183	16,683	42,511
	EBITDA (Pre 24 7 Cost)	5,712	377	1,308	7,398
	margin (%)	25.2%	11.9%	7.8%	17.4%
	24/7 Operating Cost			-1,524	-1,524
	ESOP(Non Cash expense)			-220	-220
Q2 FY 23	EBITDA	5,712	377	-436	5,654
QETTES	margin (%)	25.2%	11.9%	-	13.3%
	EBIT	4,515	132	-543	4,104
	margin (%)	19.9%	4.1%	-	9.7%
	PBT	3,983	-10	-702	3,271
	margin (%)	17.6%	-	- *	7.7%
	PAT (Reported)	2,744	-13	-692	2,040
YOY Growth					
levenue		12%	11%	17%	14%
BITDA (Pre 24)	7 Cost)	11%	-16%	21%	11%

Overall Consolidated **Revenue grew by** 14% to ₹ 48,469 mio.

- HCS Revenue grew by **12%**
- AHLL grew by **11%**
- Apollo HealthCo grew by **17%**

EBITDA excluding 24|7 cost increased by 11% to ₹ 8,248 mio.

Consolidated PAT grew by 14%.

Consolidated Financials H1 FY24



₹ Mio		Healthcare Services	Diagnostics & Retail Health (AHLL)	Digital Health & Pharmacy Distribution (AHE)	Consol		HCS	Health Co	AHLL
	Total Revenues	48,409	6,730	37,508	92,647				
	EBITDA (Pre 24 7 Cost)	11,767	550	3,060	15,377	Gross Debt	21,543	5,994	2,563
	margin (%)	24.3%	8.2%	8.2%	16.6%	Gross Debt	21,040	3,334	2,000
	24/7 Operating Cost			-3,370	-3,370				
	ESOP(Non Cash expense)			-643	-643	Cash & Cash	13,520	532	833
H1 FY 24	EBITDA	11,767	550	-953	11,365	Equivalents	,		
	margin (%)	24.3%	8.2%	-	12.3%				
	EBIT	9,333	-72	-1,199	8,062	Net Debt	8,024	5,463	1,730
	margin (%)	19.3%	-	-	8.7%		- , -		-,
	PBT	8,355	-363	-1,502	6,490	Includes investments in liquid funds and FDs of ₹ 10,1		nd FDs of ₹ 10,16	i0 mio
	margin (%)	17.3%	-	-	7.0%		_		
	PAT (Reported)	5,775	-277	-1,503	3,995				
						-			
	Total Revenues	42,879	6,113	31,475	80,467		Concel		
	EBITDA (Post Ind AS 116) (Pre 24 7 Cost)	10,556	672	2,490	13,717		Consol Gross Debt	30,10	0
	margin (%)	24.6%	11.0%	7.9%	17.0%		GIUSS DEDI		
	24/7 Operating Cost	0	0	-2,936	-2,936				
				-220	-220		Consol Net	15,2 ⁻	16
	EBITDA (Post Ind AS 116)	10,556	672	-667	10,561		Debt		
H1 FY 23	margin (%)	24.6%	11.0%	-	13.1%				
	EBIT	8,220	192	-879	7,533				
	margin (%)	19.2%	3.1%	-	9.4%				
	РВТ	7,114	-98	-1,203	5,813				
	margin (%)	16.6%	-	-	7.2%	H1FY23 ¹ :Excep	tional item Defe	erred Tax revers	sal on
	PAT (Normalized for exceptional charge / write back) ¹	4,969	-72	-1,152	3,745	migration to lowe			
	Add: Exceptional item				1,466]	-		
	PAT (Reported)				5,211				
Revenue		13%	10%	19%	15%				10
EBITDA (Pre 24 7	' Cost)	11%	-18%	23%	12%				





Healthcare Services

Hospitals

Consolidated Healthcare Services Performance



₹ Mio	Q2 FY24	Q2 FY23	ΥοΥ
No of Hospitals	44	44	
Operating beds	7765	7872	-1%
Occupancy	68%	68%	
Revenue	25,472	22,645	12%
EBITDA (Post Ind AS 116)	6,344	5,712	11%
margin (%)	24.9%	25.2%	- 32 bps
EBIT	5,123	4,515	13%
margin (%)	20.1%	19.9%	17 bps
РВТ	4,625	3,983	16%
РАТ	3,136	2,744	14%
Margin	12.3%	12.1%	19 bps

Capital employed excl CWIP* (H1 24)	66,871	ROCE 28%	
--	--------	----------	--

*CWIP of ₹ 7,399 mio towards new projects under development

H1 FY24	H1 FY23	YoY
44	44	
7765	7872	-1%
65%	64%	
48,409	42,879	13%
11,767	10,556	11%
24.3%	24.6%	- 31 bps
9,333	8,220	14%
19.3%	19.2%	11 bps
8,355	7,114	17%
5,775	4,969	16%
11.9%	11.6%	34 bps

HCS Revenue grew by 12% in Q2FY24 (Volume growth of 4% price and case mix of 8%).

Self pay and Insurance grew by 14% in Revenue vs Q2FY23 ; aided by strong surgical mix.

International patients revenue witnessed 20% increase in Q2FY24.

ARPOB¹ grew by **14%** to **₹57,391 in Q2FY24** ; ₹57,581 growth of 13% in H1 FY24

¹ARPOB is net of fees paid to "fee for service doctors" and is netted off in the Reported Revenues.

Region wise Operational Parameters Q2FY24



		Total ⁽⁷⁾			Tamilnadu Region			AP, Telengana Region			Karnataka Region		
		lotai		(Che	(Chennai & ROTN) ⁽¹⁾			(Hyderabad & others) ⁽²⁾			(Bangalore & others) ⁽³⁾		
Particulars	Q2 FY 23	Q2 FY 24	yoy (%)	Q2 FY 23	Q2 FY 24	yoy (%)	Q2 FY 23	Q2 FY 24	yoy (%)	Q2 FY 23	Q2 FY 24	yoy (%)	
No. of Operating beds	7,872	7,765		2,151	2,049		1,297	1,270		761	718		
Inpatient volume	143,387	149,197	4.1%	37,979	37,868	-0.3%	20,948	20,475	-2.3%	16,033	16,874	5.2%	
Outpatient volume ⁽⁸⁾	490,961	513,745	4.6%	159,343	146,737	-7.9%	52,266	61,147	17.0%	48,338	55,296	14.4%	
Inpatient ALOS (days)	3.44	3.26		3.30	3.08		3.67	3.45		3.16	2.85		
Bed Occupancy Rate (%)	68%	68%		63%	62%		64%	60%		72%	73%		
Inpatient revenue (₹ mio)	NA	NA		6,214	6,536	5.2%	2,979	3,306	11.0%	2,240	2,453	9.5%	
Outpatient revenue (₹ mio)	NA	NA		1,917	2,208	15.2%	582	676	16.2%	411	477	16.2%	
ARPOB (₹ /day) ⁽⁹⁾	50,353	57,391	14.0%	64,801	75,076	15.9%	46,280	56,359	21.8%	52,295	61,011	16.7%	
Total Net Revenue (₹ mio) ⁽⁷⁾	NA	NA		8,131	8,745	7.5%	3,561	3,982	11.8%	2,651	2,931	10.5%	

	Ea	stern Regior	n ⁽⁴⁾	We	estern Regio	n ⁽⁵⁾	Northern Region ⁽⁶⁾		
Particulars	Q2 FY 23	Q2 FY 24	yoy (%)	Q2 FY 23	Q2 FY 24	yoy (%)	Q2 FY 23	Q2 FY 24	yoy (%)
No. of Operating beds	1,750	1,771		802	861		1,111	1,096	
Inpatient volume	31,445	32,715	4.0%	11,300	14,025	24.1%	25,682	27,240	6.1%
Outpatient volume ⁽⁸⁾	104,951	114,033	8.7%	57,871	57,449	-0.7%	68,192	79,083	16.0%
Inpatient ALOS (days)	3.88	3.84		3.78	3.45		2.92	2.84	
Bed Occupancy Rate (%)	76%	77%		58%	61%		73%	77%	
Inpatient revenue (₹ mio)	3,658	4,346	18.8%	1,437	1,793	24.8%	3,312	3,856	16.4%
Outpatient revenue (₹ mio)	1,029	1,204	17.0%	337	436	29.4%	591	711	20.4%
ARPOB (₹ /day) ⁽⁹⁾	38,398	44,184	15.1%	41,516	46,021	10.9%	51,958	59,081	13.7%
Total Net Revenue (₹ mio) ⁽⁷⁾	4,687	5,550	18.4%	1,774	2,229	25.7%	3,903	4,567	17.0%

Notes:

(1) Tamilnadu region includes Chennai, Madurai, Karur, Karaikudi, Trichy & Nellore.

(2) AP, Telangana Region includes Hyderabad, Karimnagar, Vizag old, Vizag new & Kakinada.

(3) Karnataka region includes Bangalore, Mysore, Jayanagar & Malleswaram.

(4) Eastern region includes Bhubaneswar, Bilaspur, Guwahati, Kolkata.

(5) Western region includes Ahmedabad, Mumbai, Nashik.

(6) Northern region includes Delhi, Lucknow and Indore

(7) Revenues under the head "Total" have not been provided as Consolidated actual results will differ from total due to proportionate consolidation.

(8) Outpatient volume represents New Registrations only.

(9) Revenues under Ind AS have been grossed up for Fixed fee Doctors & considered separately as operating cost. This was earlier being netted off from Revenues under Indian GAAP.

• Region wise Operational Parameters H1FY24



	Total ⁽⁷⁾			Tamilnadu Region (Chennai & ROTN) ⁽¹⁾			AP, Telengana Region (Hyderabad & others) ⁽²⁾			Karnataka Region (Bangalore & others) ⁽³⁾		
Particulars	H1 FY 23	H1 FY 24	yoy (%)	H1 FY 23	H1 FY 24	yoy (%)	H1 FY 23	H1 FY 24	yoy (%)	H1 FY 23	H1 FY 24	yoy (%)
No. of Operating beds	7,872	7,765		2,151	2,049		1,297	1,270		761	718	
Inpatient volume	269,898	283,043	4.9%	71,931	73,114	1.6%	38,623	39,004	1.0%	30,196	31,967	5.9%
Outpatient volume ⁽⁸⁾	953,594	972,439	2.0%	305,971	282,048	-7.8%	95,829	109,530	14.3%	93,634	102,959	10.0%
Inpatient ALOS (days)	3.41	3.27		3.27	3.11		3.61	3.42		3.07	2.83	
Bed Occupancy Rate (%)	64%	65%		60%	61%		59%	57%		67%	69%	
Inpatient revenue (₹ mio)	NA	NA		11,548	12,636	9.4%	5,621	6,240	11.0%	4,114	4,713	14.6%
Outpatient revenue (₹ mio)	NA	NA		3,728	4,187	12.3%	1,092	1,271	16.4%	778	890	14.4%
ARPOB (₹ /day) ⁽⁹⁾	51.136	57.581	12.6%	64.845	74.015	14.1%	48.208	56.338	16.9%	52.721	62.050	17.7%
Total Net Revenue (₹ mio) ⁽⁷⁾	NA	NA		15,275	16,824	10.1%	6,713	7,511	11.9%	4,892	5,604	14.6%

	Ea	stern Regior	n ⁽⁴⁾	We	estern Regio	n ⁽⁵⁾	Northern Region ⁽⁶⁾		
Particulars	H1 FY 23	H1 FY 24	yoy (%)	H1 FY 23	H1 FY 24	yoy (%)	H1 FY 23	H1 FY 24	yoy (%)
No. of Operating beds	1,750	1,771		802	861		1,111	1,096	
Inpatient volume	59,701	62,292	4.3%	20,582	24,179	17.5%	48,865	52,487	7.4%
Outpatient volume ⁽⁸⁾	205,188	213,855	4.2%	115,304	112,073	-2.8%	137,668	151,974	10.4%
Inpatient ALOS (days)	3.88	3.81		3.77	3.50		2.93	2.89	
Bed Occupancy Rate (%)	72%	73%		53%	54%		70%	76%	
Inpatient revenue (₹ mio)	6,951	8,295	19.3%	2,729	3,255	19.3%	6,294	7,485	18.9%
Outpatient revenue (₹ mio)	1,978	2,242	13.3%	661	793	19.9%	1,131	1,370	21.1%
ARPOB (₹ /day) ⁽⁹⁾	38,557	44,401	15.2%	43,684	47,873	9.6%	51,845	58,405	12.7%
Total Net Revenue (₹ mio) ⁽⁷⁾	8,929	10,537	18.0%	3,390	4,048	19.4%	7,425	8,855	19.3%

Notes:

(1) Tamilnadu region includes Chennai, Madurai, Karur, Karaikudi, Trichy & Nellore.

(2) AP, Telangana Region includes Hyderabad, Karimnagar, Vizag old, Vizag new & Kakinada.

(3) Karnataka region includes Bangalore, Mysore, Jayanagar & Malleswaram.

(4) Eastern region includes Bhubaneswar, Bilaspur, Guwahati, Kolkata.

(5) Western region includes Ahmedabad, Mumbai, Nashik.

(6) Northern region includes Delhi, Lucknow and Indore


(7) Revenues under the head "Total" have not been provided as Consolidated actual results will differ from total due to proportionate consolidation.

(8) Outpatient volume represents New Registrations only.

(9) Revenues under Ind AS have been grossed up for Fixed fee Doctors & considered separately as operating cost. This was earlier being netted off from Revenues under Indian GAAP.

Strong ROCE across Metros and Non Metros





Healthcare Services : Expansion Plan



Project	Nature	Total Beds	Census Beds	Project Cost (in Crs)	Remarks
Expected commisioning : FY25					
Gachibowli, Hyderabad	Greenfield - Asset Light	375	300	₹370	Q4 FY25
Bangalore	Brownfield	150	110	₹150	Q4 FY25
Sonarpur Kolkata	Hospital Asset Acquisition	220	180	₹240	Q4 FY25
Royal Mudhol Pune	Hospital Asset Acquisition	425	350	₹675	Upfront Deposit /Capex and deferred payment.Q1 FY25 Phase 1 - 250 beds FY26 end : Phase 2- 100 additional beds
		1,170	940	₹ 1,435	
Expected commisioning : FY26					
Gurgaon	Hospital Asset Acquisition	550	420	₹ 550	Q4 FY26
SSPM & Mysore Expansion	Brownfield	140	125	₹150	Mysore H1 FY26; SSPM H2 FY26
		690	545	₹ 700	
Expected commisioning : FY27					
OMR Medicity	Greenfield	600	500	₹725	H2 FY27
Varanasi	Greenfield	400	300	₹ 575	H2 FY27
		1,000	800	₹ 1,300	
Total		2,860	2,285	₹ 3,435	

- Continue to evaluate bolt-on-acquisitions in select Tier-1 cites and Metros
- Greenfield/ Brownfield additions in both Mumbai & Bangalore under active consideration





Executive Summary



Primary Care	 > TG-specific service lines being formulated based on micro-market environment > Focus on deep community connect and engagement > Corporate empanelment via customized portals for better utilization of employee benefits
	Rapid expansion of PCC network (400+ Centres in H1 FY24)
Diagnostics	Revenue growth of 25% YoY in H1 FY24 vs 10-12% industry average
	Improved Margin profile due to revision in channel partner share, optimizing logistics, enhanced lab utilization, platform change (dry to wet chemistry), year end landing expected in mid teens
0	Wellness segment growing month on month by 8-10%, projected to constitute 15-18% of the overall business in near future
	Test menu enhancement underway with major focus on Oncogenomics, Reproductive Diagnostics and Autoimmune.
Specialty	Cradle: Expansion in key markets across select metros to consolidate market share; 1 new centre launched in Q2 FY24 in Delhi NCR, 1 centre to be commissioned in Bangalore by end of Q3 FY24; Focus on building deeper capabilities for advanced pediatrics and comprehensive women's health
Care	Spectra: Focus on improving operational efficiencies, improving case-mix, revamping doctor engagement model
	Fertility: Revenue growth of 30% YoY in H1 FY24. Unit economics improving across the board with maturing centers

Financial Performance Q2FY24



Q2 FY24	Clinics	Diagnostics	Sugar	Dental	Dialysis	Cradles (IP)	IVF	Spectra (IP)
Network	327	2,165	66	142	126	11	17	11
Footfalls/Day*	2,681	15,943	528	242	1,938	57	45	75
Gross ARPP (Rs.)*	2,051	753	3,163	6,538	1,616	101,568	41,058	97,149

AHLL Core Revenues (excluding Covid Vaccination, Covid Testing and Isolation Centre Revenues which were one-off revenues during the Covid period) grew by 17% YoY in Q2 FY 24.

Non-Covid Diagnostics revenue (excluding Covid Testing) grew by 34% YoY in Q2 FY24.

Core revenues of primary care **grew by 23%** YOY in Q2 FY24

₹ M	io	Diagnostics	Primary Care	Specialty Care	Corporate	Intra Group	AHLL (Consol)
	Q2 FY24	1239	958	1537	0	-192	3,542
Gross Revenue	Q2 FY23	1040	880	1430	0	-167	3,183
	Q2 vs Q2	19%	9%	8%			11%
						-	
EBITDA	Q2 FY24	149	204	152	-188	0	318
Londra	Q2 FY23	148	66	278	-114	0	378
	02 5/24	420/	240/	100/		00/	00/
Margin	Q2 FY24	12%	21%	10%		0%	9%
	Q2 FY23	14%	7%	19%		0%	12%
		•	•				
EBIT	Q2 FY24	114	137	-30	-191	0	30
EDII	Q2 FY23	117	-1	133	-117	1	132
ΡΑΤ	Q2 FY24	107	97	-176	-217	0	-188
PAI	Q2 FY23	107	-15	9	-119	0	-18

* Footfalls and ARPP for diagnostics represent outpatient / external business and for Cradle and Spectra it represents Inpatient volumes. Primary care includes Clinics, Sugar, Dental and Dialysis segments. Specialty care includes Cradles and Spectra

Financial Performance H1FY24



H1 FY24	Clinics	Diagnostics	Sugar	Dental	Dialysis	Cradles (IP)	IVF	Spectra (IP)
Network	327	2,165	66	142	126	11	17	11
Footfalls/Day*	2,470	15,024	500	233	1,894	52	36	73
Gross ARPP (Rs.)*	2,055	749	3,103	6,380	1,617	103,997	39,197	101,440

AHLL revenues grew by 10% from H1FY 24

Non-Covid Diagnostics revenue (excluding Covid Testing) grew by 40% YoY in H1 FY24.


Core revenues of primary care **grew by 18%** YOY in H1 FY24

₹ Mi	io	Diagnostics	Primary Care	Specialty Care	Corporate	Intra Group	AHLL (Consol)
	H1 FY24	2314	1804	2967	0	-356	6,730
Gross Revenue	H1 FY23	1856	1730	2826	0	-300	6,113
	H1 Vs H1	25%	4%	5%			10%
EBITDA	H1 FY24	224	307	358	-340	1	550
EDITUA	H1 FY23	186	201	493	-210	1	672
N A-u-i-	H1 FY24	10%	17%	12%		0%	8%
Margin	H1 FY23	10%	12%	17%		0%	11%
FDIT	H1 FY24	158	174	-59	-346	1	-72
EBIT	H1 FY23	127	69	211	-216	1	192
PAT	H1 FY24	143	105	-263	-386	0	-402
PAI	H1 FY23	108	24	-10	-227	0	-105


* Footfalls and ARPP for diagnostics represent outpatient / external business and for Cradle and Spectra it represents Inpatient volumes. Primary care includes Clinics, Sugar, Dental and Dialysis segments. Specialty care includes Cradles and Spectra

Diagnostics : Key Parameters






Avg. Footfalls per day & Avg. gross realization per patient (INR)²



- 1. Covid Revenues include RTPCR and Antibody test revenues; exclude Covid Allied tests
- 2. EBITDA post IND AS 116;

* Footfalls and ARPP for diagnostics represent outpatient / external business



Network Growth – Collection Centers






Digital Health & Pharmacy Distribution Apollo Health Co

India's Largest Omni-Channel Healthcare Platform





Apollo HealthCo Financials Q2 FY24


-826



₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total Health Co
	Total Revenues	17,143	2,312	19,454
	EBITDA*	1,304	283	1,586
	margin (%)	7.60%	12.2%	8.2%
	24 7 Operating Cost		-1,622	-1,622
0.2 51/ 24	ESOP Non Cash Charge		-351	-351
Q2 FY 24	EBITDA	1,304	-1,690	-387
	margin (%)	7.6%	-	-
	EBIT			-512
	PBT			-677
	PAT(Reported)			-678
	Total Revenues	16,001	2,053	18,054
	EBITDA*	1,250	223	1,473
	margin (%)	7.81%	10.88%	8.16%
	24 7 Operating Cost		-1,747	-1,747
	ESOP Non Cash Charge		-292	-292
Q1 FY 24	EBITDA	1,250	-1,816	-566
	margin (%)	7.8%	-	-
	EBIT			-687
	РВТ			-825

* Excluding 24|7 operating Cost and ESOP Non-Cash Charge

PAT(Reported)



Healthco (Q2'FY 24 vs Q1'FY 24) :

- 8% growth in revenue in Q2' FY24 vs Q1' FY24
- 32% reduction in EBITDA losses in Q2' FY24 (Rs 387 Mn) vs Q1' FY24 (Rs 566 Mn) on account of reduction in digital operating cost and increase in operational revenue coming from Pharmacy distribution.
- Expect to break-even in Q3' FY24 pre-ESOP and post ESOP in Q4' FY24

Omnichannel Pharmacy:

- Omnichannel Pharmacy Business revenue of Rs 24,770 Mn in Q2' FY24 compared to a revenue of Rs 20,497 Mn in Q2' FY23 (growth of 21%).
 - Online grew 38% in Q2 FY24 vs Q2 FY23 ;
 - Offline grew 19% in Q2 FY24 vs Q2 FY'23
 - Private label sales/ generic sales at 16.5%.

On track to achieve Rs 10,000 cr of revenues with 6% EBITDA in current fiscal year.

Digital Operational Metrics :

Platform GMV : Rs 7,256 Mn in Q2'FY24, growth of 147% over Q2' FY23 and 16% growth over Q1' FY24.

Continuous Improvement in quantitative parameters in Q2' FY24 vs Q2' FY23;

- Pharma AOV grew by 8% (Rs 956 vs Rs 885 a year back)
- Transacting user base grew by 29% (12.8 lakh vs 9.9 lakh, a year back)

Offline segment :


- 18% YoY growth in transactions (6.9 cr Vs 5.8 cr year back).
- Serving ~7.5 lac customers per day
- Net Addition of 669 new stores (5,671 stores in Q2' FY 24 vs 5,002 stores ending Q2'FY 23)

Apollo HealthCo Financials H1FY24

+	>

₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total Health Co
	Total Revenues	33,143	4,365	37,508
	EBITDA*	2,554	506	3,060
	margin (%)	7.70%	11.59%	8.16%
	24 7 Operating Cost	0	-3,370	-3,370
H1 FY24	ESOP Non Cash Charge	0	-643	-643
F1 F124	EBITDA	2,554	-3,506	-953
	margin (%)	7.7%	-	-
	EBIT			-1,199
	РВТ			-1,502
	PAT(Reported)			-1,503





Healthco :

- o Platform GMV : Rs 13,486 Mn in H1' FY24, growth of 165% over H1' FY23
- 19% growth in revenue in H1' FY24 vs H1' FY23

 31% reduction in EBITDA losses (pre- ESOP) to Rs. 310 Mn in H1' FY 24 from Rs. 446 Mn in H1' FY 23.

Omnichannel Pharmacy:

- Omnichannel Pharmacy Business revenue of Rs 47,234 Mn in H1' FY24 compared to a revenue of Rs 38,578 Mn in H1' FY23 (growth of 22%)
 - Online grew 47% in H1 FY24 vs H1 FY23 ;
 - Offline grew 20% in H1 FY24 vs H1 FY'23
 - Private label sales/ generic sales at 16%.






Basis of Consolidation

+ > 🐳

AHEL Standalone Hospitals (100% Ownership)	Location	
Chennai Main	Chennai	Subsidiarie Material Subs
ACI - Chennai	Chennai	Apollo Health Co limited
Tondiarpet - Chennai	Chennai	Apollo Health and Lifestyle
•		Apollo Multispeciality Hosp
FirstMed - Chennai	Chennai	Apollo Medics
Apollo Children's Hospital	Chennai	Imperial Hospital and Resea
Apollo Specialty, Vanagaram	Chennai	Apollo Hospitals Internation
ASH Perungudi	Chennai	Assam Hospitals Ltd
Women & Child, Shafee Mohammed Road	Chennai	Apollo Rajshree Hospital
Apollo Proton & Cancer care	Chennai	Samudra Healthcare Enterp
Madurai	Madurai	Other Subs
Karur	Karur	Apollo Hospitals (UK) Ltd
Karaikudi	Karaikudi	AB Medical Centres Limited
		Total Health
Trichy	Trichy	Apollo Hospitals Singapore.
Nellore	Nellore	Future Parking Pvt Ltd
Hyderabad	Hyderabad	Apollo Home Health care Lt
Bilaspur	Bilaspur	Pinakini Hospitals Ltd.
Mysore	Mysore	Sapien Bioscienses Pvt Ltd
Vizag (old & new)	Vizag	Apollo Lavasa Health Corpo
Karim Nagar	Karim Nagar	Apollo Hospitals North Limi Kerala First Health Services
Bhubaneswar	Bhubaneswar	Associates
		Indraprastha Medical Corpo
Jayanagar	Bangalore	Family Health Plan Ltd.
Nashik	Nashik	ApoKos Rehab Pvt Ltd
Malleswaram	Bangalore	Stemcyte India Therapautic
Navi Mumbai	Mumbai	Apollo Gleneagles PET-CT P

Subsidiaries	Location	Description	AHEL Ownership
Material Subs			· ·
Apollo Health Co limited	India	Digital Omni-Channel Healthcare services	100.00%
Apollo Health and Lifestyle Ltd.	India	Clinics, Diagnostics and Daycare	68.84%
Apollo Multispeciality Hospitals Ltd.	Kolkata	Hospital	100.00%
Apollo Medics	Lucknow	Hospital	51.00%
Imperial Hospital and Research Centre Ltd.	Bangalore	Hospital	90.00%
Apollo Hospitals International Ltd.	Ahmedabad	Hospital	50.00%
Assam Hospitals Ltd	Assam	Hospital	70.03%
Apollo Rajshree Hospital	Indore	Hospital	54.63%
Samudra Healthcare Enterprises Ltd.	Kakinada	Hospital	100.00%
Other Subs			
Apollo Hospitals (UK) Ltd	UK	UK Hold Co	100.00%
AB Medical Centres Limited	Chennai	Infrastructure	100.00%
Total Health	India	CSR	100.00%
Apollo Hospitals Singapore.PTE Limited	Singapore	Singapore Hold Co	100.00%
Future Parking Pvt Ltd	Chennai	Infrastructure	100.00%
Apollo Home Health care Ltd	India	Paramedical Services	89.69%
Pinakini Hospitals Ltd.	Nellore	Hospital	80.87%
Sapien Bioscienses Pvt Ltd	Hyderabad	Biobanking tissues	70.00%
Apollo Lavasa Health Corporation Ltd	Maharashtra	Hospital	51.00%
Apollo Hospitals North Limited	Gurgaon	Hospital	100.00%
Kerala First Health Services Private Limited	Kerala	Hospital	60.00%
Associates	Location	Description	
Indraprastha Medical Corporation Ltd.	Delhi, Noida	Hospital	22.03%
Family Health Plan Ltd.	India	TPA, Health Insurance	49.00%
•	Hyderabad	Rehab Centre	50.00%
	India	Stemcell Banking	37.75%
Apollo Gleneagles PET-CT Pvt Ltd	Hyderabad	Diagnostics	50.00%





Note: Accounting increase in Assets & Liabilities in the Balance sheet (due to Right of Use Asset) optically supresses the ROCE and increases the leverage ratios. No real impact in actual business ROCE. Ind AS 116 applicable from Apr 01,2019.



Thank you !